<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between November 1976 and May 1990, twenty-six patients with <z:hpo ids='HP_0002639'>Budd-Chiari syndrome</z:hpo> underwent 28 liver transplants in the Cambridge-Kings College Hospital program </plain></SENT>
<SENT sid="1" pm="."><plain>Twelve patients were male, average age 36.6 (range 19-54) and fourteen were female, average age 26 (range 10-47) </plain></SENT>
<SENT sid="2" pm="."><plain>Possible aetiological factors were identified in 13 cases; <z:mp ids='MP_0002872'>polycythaemia</z:mp> rubra vera (4), megakaryocytosis (2), <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> (1), trauma (1), pregnancy (1), oral contraceptive pill (4) </plain></SENT>
<SENT sid="3" pm="."><plain>Because of the high incidence of thrombotic complications a protocol of early anticoagulation was introduced early in the series commencing with subcutaneous <z:chebi fb="5" ids="28304">heparin</z:chebi> and progressing to formal full anticoagulation with <z:chebi fb="5" ids="28304">heparin</z:chebi> and then long term anticoagulation with <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Twelve patients have died giving one, three and five year actuarial survival figures of 69.2%, 69.2% and 49.7% respectively, there are currently six patients alive beyond five years </plain></SENT>
<SENT sid="5" pm="."><plain>Orthotopic liver grafting in <z:hpo ids='HP_0002639'>Budd-Chiari syndrome</z:hpo> and subsequent <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> thus represents a major treatment option with good long term survival and is the optimal treatment for patients with <z:e sem="disease" ids="C0745744" disease_type="Disease or Syndrome" abbrv="">end stage liver disease</z:e> </plain></SENT>
</text></document>